Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CVS Group appoints David Wilton as its new chair

(Sharecast News) - UK veterinary service provider CVS announced the appointment of David Wilton as its new chair on Wednesday. The AIM-traded firm said Wilton, who had served as an independent non-executive director since September 2021, had over 30 years of experience in finance, corporate governance and strategic leadership.

A qualified Chartered Accountant, he had held various senior roles including chief financial officer, non-executive director, and board chair across public and private-equity backed companies.

It said his background included significant involvement in mid-cap merger and acquisition and corporate finance, notably with Rothschilds.

Prior to his appointment at CVS, Wilton held key positions such as chief financial officer of Sumo Group and group finance director of WYG.

He also served as non-executive director and chair of the audit committee at Sweett Group and Frontier Developments, respectively.

"I am delighted to take on the role of chair," said David Wilton.

"I know the business well and I look forward to supporting the executive management team even more closely as we continue to grow the business and deliver value for all of our stakeholders."

Currently, Wilton held the position of non-executive director and chair designate at Gateley Holdings.

CVS said Wilton's appointment followed a comprehensive search led by the nomination committee, supported by a recruitment firm which identified a pool of candidates.

The board said it would now begin a search for a new independent audit committee chair, adding that Wilton would continue to serve in that role until the process concluded, after which he would step down as a member of the audit committee.

"On behalf of the board and colleagues at CVS, I would like to congratulate David on his appointment as chair, and thank Deborah for her contribution during her position as Interim chair," commented chief executive officer Richard Fairman.

At 1306 BST, shares in CVS Group were down 1.78% at 961.59p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

FY turnover and profits grow at Arcontech
(Sharecast News) - Software firm Arcontech said on Monday that full-year pre-tax profits and turnover were both anticipated to come in ahead of current market expectations.
Brave Bison pre-tax profits grow in H1
(Sharecast News) - Digital advertising company Brave Bison said on Monday that adjusted pre-tax profits had grown in the six months ended 30 June, leaving it confident of its ability to meet current market expectations for FY24.
Fonix Mobile ends year ahead of market expectations
(Sharecast News) - Mobile payments and messaging technology provider Fonix Mobile reported a strong full-year financial performance in a trading update on Monday.
Tristel flags forecast-busting full-year results
(Sharecast News) - Infection prevention products manufacturer Tristel released a robust trading update for the year ended 30 June on Monday, with revenues and pre-tax profits surpassing market expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.